RxDoctor Payments Data

Alexander Chiu, MD

Otolaryngology · Seattle, WANPI 1043241771

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,500 of the $8,700 with a category attached, or 74.7%. Optinose US, Inc. accounts for 77.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $7,510 and has fallen 97.0% since, to $227 in 2025. Among otolaryngology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,700in general payments, 2019–2025

Across 26 payments — averaging $334.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$7K
  • Medtronic$507
  • Acclarent, Inc$375
  • Intersect ENT, Inc.$364
  • Arrinex, Inc.$182
  • Abbott$151
  • plus $385 from 6 others

What the payments were for

  • Consulting fees$6,50075%
  • Food & beverage$2,20025%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,700 in reported general payments places this provider in the 95th percentile of 254 otolaryngology providers in Washington.

See all otolaryngology providers in Washington

Medicare billing

Part B allowed, 2024
$52,876
Medicare patients
94
Services billed
436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab11$37,939
Azelastine Hcl23$1,618
Fluticasone Propionate53$1,073
Ipratropium Bromide14$445
Doxycycline Hyclate24$224
Mupirocin19$137
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$102
Prednisone14$31

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →